High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy-Reference-Cited by-同舟云学术

High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy

Published:2012-03-27 Issue:6 Volume:88 Page:510-517
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:

Author:

Li Zhi-Ming,Huang Jia-Jia,Xia Yi,Zhu Ying-Jie,Zhao Wei,Wei Wen-Xiao,Jiang Wen-Qi,Lin Tong-Yu,Huang Hui-Qiang,Guan Zhong-Zhen

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0609.2012.01778.x/fullpdf

Reference31 articles.

1. Diffuse large B cell lymphoma (DLBCL) in Pakistan: an emerging epidemic?;Abid;Asian Pac J Cancer Prev,2005

2. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma;Fisher;N Engl J Med,1993

3. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

4. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group;Pfreundschuh;Lancet Oncol,2006

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MRI-based radiomics signatures for preoperative prediction of Ki-67 index in primary central nervous system lymphoma;European Journal of Radiology;2024-09

2. Immunohistochemistry-based investigation of MYC, BCL2, and Ki-67 protein expression and their clinical impact in diffuse large B-cell lymphoma in upper Northern Thailand;PLOS ONE;2024-07-22

3. A mechanistic model of curative combination therapy explains lymphoma clinical trial results;2024-06-25

4. Expression and Clinical Significance of Ki-67, CD10, BCL6, MUM1, c-MYC, and EBV in Diffuse Large B Cell Lymphoma Patients;Applied Immunohistochemistry & Molecular Morphology;2024-06-14

5. miR-28-based combination therapy impairs aggressive B cell lymphoma growth by rewiring DNA replication;Cell Death & Disease;2023-10-18